VRTX in the 13F filings
Vertex Pharmaceuticals Inc · CUSIP 92532F100
- Quarter end
- 30 Sep 2024
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 31 Oct 2024
- Managers listing it
- 27
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q2 2024 and Q3 2024; 24 listed it in both
- Shares listed
- 72,060,778
- combined, among listed positions
- Reported value
- $33.5bn
- combined, at the quarter end
Among the 94 comparable managers: 17 buyers (opened or added shares) and 10 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing VRTX in Q3 2024
27 of 27 holders
Largest increases and reductions, by shares
Increases
- Wellington Management Group LLPexisting position · 4,798,870 shares now+704,421
- Capital Research Global Investorsexisting position · 9,002,205 shares now+462,866
- MFS Investment Managementexisting position · 2,905,705 shares now+159,693
- AllianceBernstein LPexisting position · 7,372,767 shares now+151,695
- Invesco Ltdexisting position · 1,943,604 shares now+140,862
Reductions
- T. Rowe Price Associates Incexisting position · 1,768,010 shares now-443,664
- Fidelity (FMR LLC)existing position · 10,525,013 shares now-204,415
- Two Sigma Investments LPexisting position · 160,535 shares now-171,452
- Man Group PLCexisting position · 51,718 shares now-145,578
- Two Sigma Advisers LPexisting position · 29,400 shares now-142,400
New positions and exits
New (3)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 13 | $5.0bn | n.a. | n.a. |
| Q3 2013 | 12 | $4.6bn | n.a. | n.a. |
| Q4 2013 | 9 | $4.8bn | n.a. | n.a. |
| Q1 2014 | 11 | $4.9bn | n.a. | n.a. |
| Q2 2014 | 11 | $7.3bn | n.a. | n.a. |
| Q3 2014 | 14 | $9.0bn | n.a. | n.a. |
| Q4 2014 | 15 | $9.3bn | n.a. | n.a. |
| Q1 2015 | 21 | $9.2bn | n.a. | n.a. |
| Q2 2015 | 23 | $9.4bn | n.a. | n.a. |
| Q3 2015 | 22 | $8.3bn | n.a. | n.a. |
| Q4 2015 | 19 | $10.2bn | n.a. | n.a. |
| Q1 2016 | 18 | $6.8bn | n.a. | n.a. |
| Q2 2016 | 13 | $7.5bn | n.a. | n.a. |
| Q3 2016 | 14 | $7.7bn | n.a. | n.a. |
| Q4 2016 | 14 | $6.3bn | n.a. | n.a. |
| Q1 2017 | 21 | $9.5bn | n.a. | n.a. |
| Q2 2017 | 24 | $11.0bn | n.a. | n.a. |
| Q3 2017 | 28 | $12.6bn | n.a. | n.a. |
| Q4 2017 | 24 | $12.2bn | n.a. | n.a. |
| Q1 2018 | 24 | $13.3bn | n.a. | n.a. |
| Q2 2018 | 27 | $14.0bn | n.a. | n.a. |
| Q3 2018 | 26 | $15.7bn | n.a. | n.a. |
| Q4 2018 | 27 | $14.6bn | n.a. | n.a. |
| Q1 2019 | 26 | $17.0bn | n.a. | n.a. |
| Q2 2019 | 24 | $17.0bn | n.a. | n.a. |
| Q3 2019 | 25 | $16.0bn | n.a. | n.a. |
| Q4 2019 | 29 | $20.0bn | n.a. | n.a. |
| Q1 2020 | 27 | $20.9bn | n.a. | n.a. |
| Q2 2020 | 27 | $23.4bn | n.a. | n.a. |
| Q3 2020 | 31 | $21.9bn | n.a. | n.a. |
| Q4 2020 | 30 | $18.4bn | n.a. | n.a. |
| Q1 2021 | 31 | $15.4bn | n.a. | n.a. |
| Q2 2021 | 30 | $12.7bn | n.a. | n.a. |
| Q3 2021 | 35 | $10.1bn | n.a. | n.a. |
| Q4 2021 | 28 | $12.4bn | n.a. | n.a. |
| Q1 2022 | 23 | $16.1bn | n.a. | n.a. |
| Q2 2022 | 25 | $18.1bn | n.a. | n.a. |
| Q3 2022 | 22 | $18.4bn | n.a. | n.a. |
| Q4 2022 | 28 | $18.4bn | n.a. | n.a. |
| Q1 2023 | 26 | $21.4bn | n.a. | n.a. |
| Q2 2023 | 27 | $24.7bn | n.a. | n.a. |
| Q3 2023 | 33 | $24.3bn | n.a. | n.a. |
| Q4 2023 | 32 | $28.6bn | 16 | 16 |
| Q1 2024 | 31 | $29.8bn | 16 | 19 |
| Q2 2024 | 29 | $33.4bn | 12 | 18 |
| Q3 2024 | 27 | $33.5bn | 17 | 10 |
| Q4 2024 | 26 | $28.5bn | 14 | 13 |
| Q1 2025 | 21 | $35.4bn | 10 | 11 |
| Q2 2025 | 21 | $32.3bn | 11 | 11 |
| Q3 2025 | 22 | $25.9bn | 13 | 10 |
| Q4 2025 | 26 | $31.8bn | 19 | 20 |
| Q1 2026 | 25 | $31.8bn | 17 | 21 |
| Q2 2026 | 26 | $34.6bn | 21 | 17 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
VRTX and LLY →VRTX and JNJ →VRTX and GILD →Choose a stock to compare with VRTX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own VRTX, latest filings →Back to the 13F Explorer →